Literature DB >> 26209220

Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma.

Tracy Donahue1, Christina Y Lee1, Asmi Sanghvi1, Roxana Obregon1, Michael Sidiropoulos1, Chelsea Cooper1, Emily A Merkel1, Oriol Yélamos1, Laura Ferris2, Pedram Gerami3.   

Abstract

BACKGROUND: A number of factors other than those identified by the American Joint Committee on Cancer (AJCC) may have prognostic significance in the evaluation of melanoma.
OBJECTIVE: We sought to evaluate commonly recorded clinical features potentially associated with aggressive melanoma.
METHODS: We conducted a retrospective case-control study. We included patients given a diagnosis of cutaneous melanoma with at least 5 years of follow-up or documented metastases. Patients were divided into nonaggressive and aggressive groups. Univariate and multivariate statistical analyses were performed to evaluate the association of multiple clinical and histologic parameters and metastases.
RESULTS: We included 141 patients. Significant prognostic factors in univariate analysis associated with nonaggressive disease included history of dysplastic nevus syndrome and ABCDE criteria. Significant factors in univariate analysis associated with aggressive disease included age and immunosuppression. Only age and immunosuppression remained significant in multivariate analysis when controlled across statistically significant histologic variables from AJCC. LIMITATIONS: The study is retrospective and has a small sample size.
CONCLUSION: Older patients and those with a history of immunosuppression may be at higher risk for aggressive disease and should be closely monitored after an initial diagnosis of melanoma.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCDE criteria; age; dysplastic nevus syndrome; immunosuppression; melanoma; metastatic melanoma

Mesh:

Substances:

Year:  2015        PMID: 26209220     DOI: 10.1016/j.jaad.2015.06.052

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival.

Authors:  Maclean Cook; Kelsey Baker; Mary Redman; Kristina Lachance; Macklin H Nguyen; Upendra Parvathaneni; Shailender Bhatia; Paul Nghiem; Yolanda D Tseng
Journal:  Am J Clin Oncol       Date:  2019-01       Impact factor: 2.339

2.  High regional mortality due to malignant melanoma in Eastern Finland may be explained by the increase in aggressive melanoma types.

Authors:  Ville Suhonen; Jaana Rummukainen; Hanna Siiskonen; Arto Mannermaa; Ilkka T Harvima
Journal:  BMC Cancer       Date:  2021-10-29       Impact factor: 4.430

3.  Flavonoid Group of Smilax glabra Roxb. Regulates the Anti-Tumor Immune Response Through the STAT3/HIF-1 Signaling Pathway.

Authors:  Yingxue Guo; Weiye Mao; Lu Jin; Linying Xia; Jie Huang; Xia Liu; Ping Ni; Qiyang Shou; Huiying Fu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.